354 related articles for article (PubMed ID: 12500228)
1. Effect of variability in anemia management on hemoglobin outcomes in ESRD.
Lacson E; Ofsthun N; Lazarus JM
Am J Kidney Dis; 2003 Jan; 41(1):111-24. PubMed ID: 12500228
[TBL] [Abstract][Full Text] [Related]
2. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.
Collins AJ; Brenner RM; Ofman JJ; Chi EM; Stuccio-White N; Krishnan M; Solid C; Ofsthun NJ; Lazarus JM
Am J Kidney Dis; 2005 Sep; 46(3):481-8. PubMed ID: 16129210
[TBL] [Abstract][Full Text] [Related]
3. Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients.
Chan K; Moran J; Hlatky M; Lafayette R
Nephrol Dial Transplant; 2009 Jun; 24(6):1956-62. PubMed ID: 19176685
[TBL] [Abstract][Full Text] [Related]
4. Changes in hemoglobin level distribution in US dialysis patients from June 2006 to November 2008.
Spiegel DM; Khan I; Krishnan M; Mayne TJ
Am J Kidney Dis; 2010 Jan; 55(1):113-20. PubMed ID: 19932539
[TBL] [Abstract][Full Text] [Related]
5. Factors affecting anemia management in hemodialysis patients: a single-center experience.
Spiegel DM; Gitlin M; Mayne T
Hemodial Int; 2008 Jul; 12(3):336-41. PubMed ID: 18638090
[TBL] [Abstract][Full Text] [Related]
6. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
7. Facility factors dominate the ability to achieve target haemoglobin levels in haemodialysis patients.
Chan KE; Lafayette RA; Whittemore AS; Hlatky MA; Moran J
Nephrol Dial Transplant; 2008 Sep; 23(9):2948-56. PubMed ID: 18469314
[TBL] [Abstract][Full Text] [Related]
8. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
Pizzarelli F; David S; Sala P; Icardi A; Casani A
Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
[TBL] [Abstract][Full Text] [Related]
9. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Pisoni RL; Bragg-Gresham JL; Young EW; Akizawa T; Asano Y; Locatelli F; Bommer J; Cruz JM; Kerr PG; Mendelssohn DC; Held PJ; Port FK
Am J Kidney Dis; 2004 Jul; 44(1):94-111. PubMed ID: 15211443
[TBL] [Abstract][Full Text] [Related]
10. [Hemoglobin variability in patients with chronic renal insuffiency].
Deray G
Nephrol Ther; 2008 Dec; 4(7):549-52. PubMed ID: 19004677
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer.
Prosnitz RG; Yao B; Farrell CL; Clough R; Brizel DM
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1087-95. PubMed ID: 15752888
[TBL] [Abstract][Full Text] [Related]
12. What is needed to achieve a hemoglobin of 11.0-13.0 g/dl in end-stage renal disease.
Fishbane S
Blood Purif; 2007; 25(1):53-7. PubMed ID: 17170538
[TBL] [Abstract][Full Text] [Related]
13. Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization.
Servilla KS; Singh AK; Hunt WC; Harford AM; Miskulin D; Meyer KB; Bedrick EJ; Rohrscheib MR; Tzamaloukas AH; Johnson HK; Zager PG
Am J Kidney Dis; 2009 Sep; 54(3):498-510. PubMed ID: 19628315
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
15. [Is the management of anemia in hemodialysis patients improving in France? Results of the DiaNE study].
Kessler M; Landais P; Canivet E; Yver L; Bataille P; Brillet G; Commenges B; Koné S
Nephrol Ther; 2009 Apr; 5(2):114-21. PubMed ID: 19042175
[TBL] [Abstract][Full Text] [Related]
16. Hemoglobin variability in epoetin-treated hemodialysis patients.
Berns JS; Elzein H; Lynn RI; Fishbane S; Meisels IS; Deoreo PB
Kidney Int; 2003 Oct; 64(4):1514-21. PubMed ID: 12969173
[TBL] [Abstract][Full Text] [Related]
17. Correlates affecting survival in chronic hemodialysis patients: the combined impact of albumin and high hemoglobin levels on improving outcomes, local and national results.
Capelli JP; Kushner H
Hemodial Int; 2008 Oct; 12(4):450-62. PubMed ID: 19090868
[TBL] [Abstract][Full Text] [Related]
18. Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed?
Berns JS
Semin Dial; 2005; 18(1):22-9. PubMed ID: 15663760
[TBL] [Abstract][Full Text] [Related]
19. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations.
Ebben JP; Gilbertson DT; Foley RN; Collins AJ
Clin J Am Soc Nephrol; 2006 Nov; 1(6):1205-10. PubMed ID: 17699349
[TBL] [Abstract][Full Text] [Related]
20. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.
Regidor DL; Kopple JD; Kovesdy CP; Kilpatrick RD; McAllister CJ; Aronovitz J; Greenland S; Kalantar-Zadeh K
J Am Soc Nephrol; 2006 Apr; 17(4):1181-91. PubMed ID: 16565261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
